Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients

Shelly Wen,1,2 Lucy Manuel,1,2 Moira Doolan,1,2 Justin Westhuyzen,1 Thomas P Shakespeare,1,2 Noel J Aherne1,2 1Department of Radiation Oncology, Mid North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia; 2University of New South Wales, Sydney, New South Wales, AustraliaCorresponden...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wen S, Manuel L, Doolan M, Westhuyzen J, Shakespeare TP, Aherne NJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	dose fractionation mastectomy radiotherapy survival analysis triple negative breast neoplasms Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3fe806037f754fe6842947b0f7c06c77
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3fe806037f754fe6842947b0f7c06c77
record_format	dspace
spelling	oai:doaj.org-article:3fe806037f754fe6842947b0f7c06c772021-12-02T03:53:16ZEffect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients1179-1314https://doaj.org/article/3fe806037f754fe6842947b0f7c06c772020-03-01T00:00:00Zhttps://www.dovepress.com/effect-of-clinical-and-treatment-factors-on-survival-outcomes-of-tripl-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Shelly Wen,1,2 Lucy Manuel,1,2 Moira Doolan,1,2 Justin Westhuyzen,1 Thomas P Shakespeare,1,2 Noel J Aherne1,2 1Department of Radiation Oncology, Mid North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia; 2University of New South Wales, Sydney, New South Wales, AustraliaCorrespondence: Noel J AherneDepartment of Radiation Oncology, Mid North Coast Cancer Institute, Coffs Harbour NSW 2450, AustraliaTel +61-2-6656-7000Fax +61-2-6656-5330Email noel.aherne@health.nsw.gov.auPurpose: Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer cases and is associated with a poor prognosis. In this retrospective study of patients undergoing radiation therapy as part of their treatment, disease-free survival (DFS) and overall survival (OS) of TNBC patients were examined in relation to clinical and treatment-related factors.Patients and Methods: The electronic records of 214 consecutive TNBC patients treated with surgery followed by radiotherapy at the Mid North Coast Cancer Institute between 2006 and 2016 were reviewed. Overall survival and DFS times were analyzed using the Kaplan-Meier method; multivariate Cox proportional hazard regression modelling was used to assess the significance of prognostic factors.Results: The majority of tumors were T1 (51.9%), followed by T2 (39.2%) and T3 (6.1%). For the whole group, mean DFS was 106.4 (SD 48.7) months; OS 109.4 (SD 52.1) months. Radiotherapy technique, fractionation protocol and laterality were not significant factors for DFS or OS (p> 0.05). However, compared to breast conservation, mastectomy was associated with poorer DFS (mean 114.2 vs 65.2 months; p< 0.0001) and poorer OS (mean 115.5 vs 80.5 months; p=0.0015). The mastectomy group had fewer patients with tumor size T1 (p=0.001) and higher proportions of T3 (p=0.001) and T4 (p=0.02). On multivariate analysis, tumor size T3/T4 and nodal status N2/N3 were significant factors for reduced DFS (p=0.023 and p=0.0003 respectively). Tumor size T3/T4 was the only significant prognostic factor for reduced OS (p=0.019).Conclusion: Advanced disease exhibited by tumor size > 5cm and positive nodal status is associated with poorer DFS in TNBC patients. Radiotherapy technique or fractionation protocol were not associated with differences in DFS or OS in our patient cohort.Keywords: dose fractionation, mastectomy, radiotherapy, survival analysis, triple negative breast neoplasmsWen SManuel LDoolan MWesthuyzen JShakespeare TPAherne NJDove Medical Pressarticledose fractionationmastectomyradiotherapysurvival analysistriple negative breast neoplasmsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 12, Pp 27-35 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	dose fractionation mastectomy radiotherapy survival analysis triple negative breast neoplasms Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	dose fractionation mastectomy radiotherapy survival analysis triple negative breast neoplasms Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Wen S Manuel L Doolan M Westhuyzen J Shakespeare TP Aherne NJ Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients
description	Shelly Wen,1,2 Lucy Manuel,1,2 Moira Doolan,1,2 Justin Westhuyzen,1 Thomas P Shakespeare,1,2 Noel J Aherne1,2 1Department of Radiation Oncology, Mid North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia; 2University of New South Wales, Sydney, New South Wales, AustraliaCorrespondence: Noel J AherneDepartment of Radiation Oncology, Mid North Coast Cancer Institute, Coffs Harbour NSW 2450, AustraliaTel +61-2-6656-7000Fax +61-2-6656-5330Email noel.aherne@health.nsw.gov.auPurpose: Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer cases and is associated with a poor prognosis. In this retrospective study of patients undergoing radiation therapy as part of their treatment, disease-free survival (DFS) and overall survival (OS) of TNBC patients were examined in relation to clinical and treatment-related factors.Patients and Methods: The electronic records of 214 consecutive TNBC patients treated with surgery followed by radiotherapy at the Mid North Coast Cancer Institute between 2006 and 2016 were reviewed. Overall survival and DFS times were analyzed using the Kaplan-Meier method; multivariate Cox proportional hazard regression modelling was used to assess the significance of prognostic factors.Results: The majority of tumors were T1 (51.9%), followed by T2 (39.2%) and T3 (6.1%). For the whole group, mean DFS was 106.4 (SD 48.7) months; OS 109.4 (SD 52.1) months. Radiotherapy technique, fractionation protocol and laterality were not significant factors for DFS or OS (p> 0.05). However, compared to breast conservation, mastectomy was associated with poorer DFS (mean 114.2 vs 65.2 months; p< 0.0001) and poorer OS (mean 115.5 vs 80.5 months; p=0.0015). The mastectomy group had fewer patients with tumor size T1 (p=0.001) and higher proportions of T3 (p=0.001) and T4 (p=0.02). On multivariate analysis, tumor size T3/T4 and nodal status N2/N3 were significant factors for reduced DFS (p=0.023 and p=0.0003 respectively). Tumor size T3/T4 was the only significant prognostic factor for reduced OS (p=0.019).Conclusion: Advanced disease exhibited by tumor size > 5cm and positive nodal status is associated with poorer DFS in TNBC patients. Radiotherapy technique or fractionation protocol were not associated with differences in DFS or OS in our patient cohort.Keywords: dose fractionation, mastectomy, radiotherapy, survival analysis, triple negative breast neoplasms
format	article
author	Wen S Manuel L Doolan M Westhuyzen J Shakespeare TP Aherne NJ
author_facet	Wen S Manuel L Doolan M Westhuyzen J Shakespeare TP Aherne NJ
author_sort	Wen S
title	Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients
title_short	Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients
title_full	Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients
title_fullStr	Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients
title_full_unstemmed	Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients
title_sort	effect of clinical and treatment factors on survival outcomes of triple negative breast cancer patients
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/3fe806037f754fe6842947b0f7c06c77
work_keys_str_mv	AT wens effectofclinicalandtreatmentfactorsonsurvivaloutcomesoftriplenegativebreastcancerpatients AT manuell effectofclinicalandtreatmentfactorsonsurvivaloutcomesoftriplenegativebreastcancerpatients AT doolanm effectofclinicalandtreatmentfactorsonsurvivaloutcomesoftriplenegativebreastcancerpatients AT westhuyzenj effectofclinicalandtreatmentfactorsonsurvivaloutcomesoftriplenegativebreastcancerpatients AT shakespearetp effectofclinicalandtreatmentfactorsonsurvivaloutcomesoftriplenegativebreastcancerpatients AT ahernenj effectofclinicalandtreatmentfactorsonsurvivaloutcomesoftriplenegativebreastcancerpatients
_version_	1718401543990935552

Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients

Ejemplares similares